ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Thrombosis and Haemostasis
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1636717
This article is part of the Research TopicInterplay of Immunothrombosis and Thromboinflammation in Health and DiseaseView all 5 articles
The Impact of Inflammatory Factors on Patients with Concurrent Lung Cancer and Acute Pulmonary Embolism
Provisionally accepted
- Second Xiangya Hospital, Central South University, Changsha, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lung cancer remains a leading cause of cancer-related mortality globally, with acute pulmonary embolism (APE) exacerbating poor prognoses in affected patients. Emerging evidence underscores the dual role of inflammatory pathways in both oncogenesis and thrombotic events. This study investigates the prognostic significance of inflammatory biomarkers, particularly neutrophil-mediated mechanisms, in lung cancer patients with APE. A retrospective cohort analysis was conducted on 90 lung cancer patients admitted to the Second Xiangya Hospital of Central 2 South University between January 2019 and December 2022. Propensity score matching (PSM) ensured balanced demographic covariates. Multivariate logistic regression revealed elevated neutrophil counts as an independent predictor of APE occurrence (adjusted OR = 3.068, 95% CI: 1.472-6.394, p = 0.003). Subgroup analysis of APE patients demonstrated that hyperuricemia (UA >260.1 µmol/L; OR = 1.017, 95% CI: 1.002-1.033, p = 0.028) and reduced platelet-to-lymphocyte ratio (PLR < 318.83; OR = 0.990, 95% CI: 0.981-0.999, p = 0.037) were significantly associated with disease severity and ICU admission. Receiver operating characteristic (ROC) curves further validated the discriminative capacity of neutrophil count (AUC = 0.952), UA (AUC = 0.782), and PLR (AUC = 0.792) in stratifying APE risk and outcomes. These findings highlight neutrophilia as a potential biomarker for APE susceptibility in lung cancer patients, while elevated UA and diminished PLR may serve as indicators of disease severity. The study emphasizes the need for integrating inflammatory markers into clinical risk assessment frameworks to optimize therapeutic strategies for this high-risk population.
Keywords: lung cancer, Acute pulmonary embolism, Hyperuricemia, Thromboinflammation, Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio
Received: 28 May 2025; Accepted: 23 Sep 2025.
Copyright: © 2025 Li, Yi, Shangjie, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wu Shangjie, wushangjie@csu.edu.cn
Yuan Li, lrruan@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.